Why Moderna, Inc. (MRNA) stock moved
Moderna, Inc. (MRNA) shares tumbled 10.8% to $68.27 as of July 11, 2026, a sharp decline from the prior close of $76.56. BestStocks flagged the session as a major change for MRNA. No single company-specific catalyst was confirmed during the move window. Below, we break down what changed for MRNA, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
MRNA fell 10.8% to $68.27
Moderna, Inc. (MRNA) moved -10.83% from $76.56 to $68.27 on 2026-07-10. We checked news, earnings, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume was near its 5-day average, indicating the move occurred without unusual trading activity. Monitor for earnings announcements, regulatory updates on pipeline programs, or sector-specific biotech/vaccine news that could explain or follow the decline.
What it means for Moderna, Inc. investors
For Moderna, Inc. investors, the recent signals add up to a bearish shift. On the constructive side: Positive price momentum. Weighing against that: Sharp 10.8% decline — elevated risk; New SEC filing — review for material disclosures. Wall Street's consensus price target sits at $46.50, implying -31.9% downside from $68.27. BestStocks rates the overall signal quality weak (0/100). With earnings roughly 20 days out, the next report is the most likely near-term test of the move.
MRNA price reaction
MRNA last traded at $68.27, down $8.29 (-10.83%) from the previous close of $76.56. The session traded on 1.2× average volume (normal), so participation was unremarkable. Over the past month the stock has ranged between $45.99 and $81.80, and it currently sits about 62% of the way up that band.
Bullish and bearish analyst opinions on Moderna, Inc. (MRNA)
The consensus analyst price target on Moderna, Inc. (MRNA) is $46.50, 31.9% below the recent $68.27. Over the past 90 days analysts logged 0 upgrades, 9 maintains, and 0 downgrades. Here is how the bullish and bearish cases on MRNA line up.
The bullish case
- The Street's most bullish target is $77.00 (+12.8%).
- Positive price momentum.
The bearish case
- The consensus analyst price target of $46.50 sits 31.9% below the recent $68.27, so the average target sees limited room to run.
- The most bearish analyst target is $35.00 (-48.7%).
- Sharp 10.8% decline — elevated risk.
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Jul 11, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for MRNA
Frequently asked questions about MRNA
Why did Moderna, Inc. (MRNA) stock move?
MRNA tumbled 10.8% to $68.27. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did MRNA stock fall?
MRNA lost 10.83% ($8.29) versus the prior close of $76.56, last trading at $68.27 on 1.2× average volume.
When is Moderna, Inc.'s next earnings date?
MRNA's next earnings report is estimated for 2026-07-31 — about 20 days away.
What is the analyst price target for MRNA?
The consensus analyst price target for MRNA is $46.50, about 31.9% below the current $68.27. Over the past 90 days, analysts recorded 0 upgrades, 9 maintains, and 0 downgrades.
How BestStocks tracks MRNA
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared MRNA-specific materiality thresholds, triggering an evidence check. It draws on 9 tracked change events for MRNA, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of July 11, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
